Outcomes of Surgical and Chemotherapeutic Treatments of Goblet Cell Carcinoid Tumors of the Appendix

Tsang, Erica S.; McConnell, Yarrow J.; Schaeffer, David F.; Lee, Lawrence; Yin, Yongjun; Zerhouni, Siham; Schaff, Kimberly; Speers, Caroline; Kennecke, Hagen F.

doi:10.1245/s10434-018-6560-0

Cited by 28 publications

(21 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our cohort, only 41.4% of patients with Stage III disease and 70.2% of patients with Stage IV disease underwent chemotherapy. This is similar to a recent study, which showed that 62.5% of Stage IV patients received adjuvant chemotherapy . In this study, there was significantly improved survival for patients with Stage III disease undergoing chemotherapy.…”

Section: Discussionsupporting

confidence: 92%

“…In terms of independent predictors of survival, older age, the presence of metastatic disease, and positive surgical margins were associated with decreased overall survival. Prior studies have linked lymph node metastasis and distant metastatic disease to overall survival . Interestingly, tumor size was not predictive of overall survival, which is consistent with prior reports evaluating GCC, but in contrast to studies of other carcinoid tumors, thus adding further evidence that GCCs are a distinct pathologic disease from other hindgut neuroendocrine tumors …”

Section: Discussionsupporting

confidence: 83%

“…Given the rarity of the disease, most information about clinical outcomes of GCC derives from small retrospective studies, often involving single institutions . There are only a few studies using cancer registry data to examine larger numbers of patients with GCC.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Treatment patterns and outcomes in goblet cell carcinoid tumors of the appendix

Fields

Enzinger

et al. 2019

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background: Goblet cell carcinoid (GCC) tumors of the appendix are a rare malignancy. We aim to examine the overall survival per stage and the relationship between different treatment modalities and outcomes for patients with GCC tumors of the appendix. Methods:We identified patients with GCC tumors of the appendix from the National Cancer Database. The main outcome was overall patient survival and cox proportional hazard models were used to ascertain predictors of survival.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 83%

See 1 more Smart Citation

Treatment patterns and outcomes in goblet cell carcinoid tumors of the appendix

Fields

Enzinger

et al. 2019

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…71 This together with other smaller studies have shown that CRS with HIPEC may be considered for select patients with peritoneal metastases from GCA. 68,72,73…”

Section: Goblet Cell Adenocarcinoma/mixed Adenoneuroendocrine Carcinomamentioning

confidence: 99%

The Landmark Series: Appendiceal Primary Peritoneal Surface Malignancy

Gangi

Shah

2021

Ann Surg Oncol

View full text Add to dashboard Cite

Appendiceal primary peritoneal surface malignancies are rare and include a broad spectrum of pathologies ranging from indolent disease to aggressive disease. As such, the data that drive the management of appendiceal peritoneal surface malignancies is generally not based on prospective clinical trial data, but rather consists of level 1 data based on retrospective studies and high-volume institutional experiences. Complete surgical debulking typically offers the best chance for long-term survival. This review highlights the landmark articles on which management of primary appendiceal peritoneal surface malignancies are based.Appendiceal neoplasms are rare and involve a spectrum of diseases that can be either low grade with fairly slow growth rates or high grade with aggressive features. Broadly, appendiceal neoplasms account for only 1-2 % of intestinal malignancies. 1,2 Appendiceal malignancies may present with acute appendicitis, or more frequently, with progressive abdominal discomfort. Patients with appendiceal cancers may also be asymptomatic, and diagnosed secondary to identification of an abnormality noted on cross-sectional imaging, at the time of colonoscopy with an abnormal-appearing appendiceal orifice or at the time of surgery for another indication.

show abstract

“…9 However, at present, the evidence for CRS-HIPEC as treatment for PM of GCCs and MANECs is unclear and the current literature on this subject consists of relatively small, noncomparative, retrospective cohort studies presenting heterogeneous outcomes. 2,3,10,11 The lack of evidence to support this multimodality approach stresses the importance of evaluating its value in a well-defined cohort of GCC and MANEC patients. Therefore, the aims of the present study were: (1) to present available evidence in a systematic review of the literature and (2) to compare clinical outcomes of GCC and MANEC patients with PM treated with CRS-HIPEC to patients that underwent surgery without HIPEC using an international multicenter cohort together with a nationwide cancer database.…”

Section: Introductionmentioning

confidence: 99%